Booster dose after 10 years is recommended following 17DD-YF primary vaccination

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 2, 2016, Pages 491-502

  Campi Azevedo, Ana Carolina ^a   Costa Pereira, Christiane ^a   Antonelli, Lis R ^a   Fonseca, Cristina T ^a   Teixeira Carvalho, Andréa ^a   Villela Rezende, Gabriela ^a   Santos, Raiany A ^a   Batista, Maurício A ^a   Campos, Fernanda M ^a   Pacheco Porto, Luiza ^a   Melo Júnior, Otoni A ^a   Hossell, Débora M S H ^a   Coelho dos Reis, Jordana G ^a   Peruhype Magalhães, Vanessa ^a   Costa Silva, Matheus F ^a   de Oliveira, Jaquelline G ^a   Farias, Roberto H ^a   Noronha, Tatiana G ^a   Lemos, Jandira A ^b   von Doellinger, Vanessa dos R ^a   Simões, Marisol ^a   de Souza, Mirian M ^a   Malaquias, Luiz C ^c   Persi, Harold R ^d   Pereira, Jorge M ^d   Martins, José A ^d   Dornelas Ribeiro, Marcos ^d   Vinhas, Aline de A ^d   Alves, Tatiane R ^d   Maia, Maria de L ^a   Freire, Marcos da S ^a   Martins, Reinaldo de M ^a   Homma, Akira ^a   Romano, Alessandro P M ^e   Domingues, Carla M ^e   Tauil, Pedro L ^f   Vasconcelos, Pedro F ^g   Rios, Maria ^h   Caldas, Iramaya R ^a   Camacho, Luiz A ^a   Martins Filho, Olindo Assis ^a   more..

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Secretaria de Estado de Saúde Governo do Estado de Minas Gerais Belo Horizonte   (Brazil)

^c FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^d Inst de Biologia do Exército   (Brazil)

^e MINISTÉRIO DA SAÚDE   (Brazil)

^f UNIVERSITY OF BRASILIA   (Brazil)

^g INSTITUTO EVANDRO CHAGAS   (Brazil)

^h CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

cytokine; duration of immunity; flow cytometry; memory cells and vaccination; vaccine; yellow fever

Indexed keywords

CD27 ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; YELLOW FEVER VACCINE; TUMOR NECROSIS FACTOR; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DRUG DOSAGE FORM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; LYMPHOCYTE CULTURE; MALE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRACTICE GUIDELINE; PROTEIN PROTEIN INTERACTION; SINGLE DRUG DOSE; SYSTEMS BIOLOGY; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS NEUTRALIZATION; B LYMPHOCYTE; BLOOD; BRAZIL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; VIROLOGY; YELLOW FEVER; YELLOW FEVER VIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BRAZIL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84960947043     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1082693     Document Type: Article

References (29)

1. T.P.Monath. Yellow fever: an update. Lancet Infect Dis 2001; 1:11-20; PMID:11871403; http://dx.doi.org/10.1016/S1473-3099(01)00016-0
2. J.D.Poland, C.H.Calisher, T.P.Monath, W.G.Downs, K.Murphy. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59: 895-900; PMID:6978196
3. R.S.Akondy, N.D.Monson, J.D.Miller, S.Edupuganti, D.Teuwen, H.Wu, F.Quyyumi, S.Garg, J.D.Altman, C.Del Rio, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009; 183:7919-30; PMID:19933869; http://dx.doi.org/10.4049/jimmunol.0803903
4. Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine 2014; 32:4977-84; PMID:25090646; http://dx.doi.org/10.1016/j.vaccine.2014.07.021
5. E.Gotuzzo, S.Yactayo, E.Córdova. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013; 89:434-44; PMID:24006295; http://dx.doi.org/10.4269/ajtmh.13-0264
6. D.Gaucher, R.Therrien, N.Kettaf, B.R.Angermann, G.Boucher, A.Filali-Mouhim, J.M.Moser, R.S.Mehta, D.R.Drake, E.Castro, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119-31; PMID:19047440; http://dx.doi.org/10.1084/jem.20082292
7. M.R.Bassi, M.Kongsgaard, M.A.Steffensen, C.Fenger, M.Rasmussen, K.Skjødt, B.Finsen, A.Stryhn, S.Buus, J.P.Christensen, A.R.Thomsen. CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol 2015; 194: 1141-53; PMID:25539816; http://dx.doi.org/10.4049/jimmunol.1402605
8. T.D.Querec, S.A.Rama, E.K.Lee, W.Cao, H.I.Nakaya, D.Teuwen, A.Pirani, K.Gernert, J.Deng, B.Marzolf, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2008; 10:116-25; PMID:19029902; http://dx.doi.org/10.1038/ni.1688
9. T.P.Monath, R.Nichols, W.T.Archambault, L.Moore, R.Marchesani, J.Tian, R.E.Shope, N.Thomas, R.Schrader, D.Furby, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66: 533-41; PMID:12201587
10. E.Muyanja, A.Ssemaganda, P.Ngauv, R.Cubas, H.Perrin, D.Srinivasan, G.Canderan, B.Lawson, J.Kopycinski, A.S.Graham, et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 2014; 124:3147-58
11. (WHO) 2008. WHO: Expert Committee on Biological Standardization: Requirements for yellow fever vaccine. In Bolletin Requirements for Biological Substances. Geneve: WHO.
12. A.C.Campi-Azevedo, L.P.de Araújo-Porto, M.Luiza-Silva, M.A.Batista, M.A.Martins, R.Sathler-Avelar, D.da Silveira-Lemos, L.A.Camacho, M.R.de Menezes, S.de Lourdes de. et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS One 2012; 7(12):e49828; PMID:23251351; http://dx.doi.org/10.1371/journal.pone.0049828
13. M.A.Martins, M.L.Silva, A.P.Marciano, V.Peruhype-Magalhães, S.M.Eloi-Santos, J.G.Ribeiro, R.Correa-Oliveira, A.Homma, E.G.Kroon, A.Teixeira-Carvalho, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol 2007; 148:90-100; PMID:17309541; http://dx.doi.org/10.1111/j.1365-2249.2006.03317.x
14. R.Ravindran, N.Khan, H.I.Nakaya, S.Li, J.Loebbermann, M.S.Maddur, Y.Park, D.P.Jones, P.Chappert, J.Davoust, et al. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science 2014; 343:313-7; PMID:24310610; http://dx.doi.org/10.1126/science.1246829
15. L.K.Mackay, A.T.Stock, J.Z.Ma, C.M.Jones, S.J.Kent, S.N.Mueller, W.R.Heath, F.R.Carbone, T.Gebhardt. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012; 109:7037-42; PMID:22509047; http://dx.doi.org/10.1073/pnas.1202288109
16. W.G.Tan, H.T.Jin, E.E.West, P.Penaloza-MacMaster, A.Wieland, M.J.Zilliox, M.J.McElrath, D.H.Barouch, R.Ahmed. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 2013; 87:1359-72; PMID:23175355; http://dx.doi.org/10.1128/JVI.02055-12
17. K.Virnik, M.Hockenbury, Y.Ni, J.Beren, G.N.Pavlakis, B.K.Felber, I.Berkower. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. Retrovirology 2013; 10-99; PMID:23369348
18. G.J.Hatch, V.A.Graham, K.R.Bewley, J.A.Tree, M.Dennis, I.Taylor, S.G.Funnell, S.R.Bate, K.Steeds, T.Tipton, T.Bean, L.Hudson, D.J.Atkinson, G.McLuckie, M.Charlwood, A.D.Roberts, J.Vipond. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol 2013; 87:7805-15; PMID:23658452; http://dx.doi.org/10.1128/JVI.03481-12
19. J.E.Ledgerwood, K.Zephir, Z.Hu, C.J.Wei, L.Chang, M.E.Enama, C.S.Hendel, S.Sitar, R.T.Bailer, R.A.Koup, J.R.Mascola, G.J.Nabel, B.S.Graham. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 208:418-22; PMID:23633407; http://dx.doi.org/10.1093/infdis/jit180
20. S.Khurana, J.Wu, M.Dimitrova, L.R.King, J.Manischewitz, B.S.Graham, J.E.Ledgerwood, H.Golding. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013; 208:413-7; PMID:23633404; http://dx.doi.org/10.1093/infdis/jit178
21. K.Odunsi, J.Matsuzaki, J.Karbach, A.Neumann, P.Mhawech-Fauceglia, A.Miller, A.Beck, C.D.Morrison, G.Ritter, H.Godoy, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012; 109:5797-802; PMID:22454499; http://dx.doi.org/10.1073/pnas.1117208109
22. J.J.Campbell, K.E.Murphy, E.J.Kunkel, C.E.Brightling, D.Soler, Z.Shen, J.Boisvert, H.B.Greenberg, M.A.Vierra, S.B.Goodman, et al. CCR7 expression and memory T cell diversity in humans. J. Immunol 2001; 166:877-84; PMID:11145663; http://dx.doi.org/10.4049/jimmunol.166.2.877
23. M.Simões, L.A.B.Camacho, A.M.Y.Yamamura, E.H.Miranda, A.C.R.A.Cajaraville, M.S.Freire. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 2012; 40:399-404; PMID:23034357; http://dx.doi.org/10.1016/j.biologicals.2012.09.005
24. B.Reinhardt, R.Jaspert, M.Niedrig, C.Kostner, J.L'age-Stehr. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56: 159-67; PMID:9746073; http://dx.doi.org/10.1002/(SICI)1096-9071(199810)56:2%3c159::AID-JMV10%3e3.0.CO;2-B
25. J.D.Miller, R.G.van der Most, R.S.Akondy, J.T.Glidewell, S.Albott, D.Masopust, K.Murali-Krishna, P.L.Mahar, S.Edupuganti, S.Lalor, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710-22; PMID:18468462; http://dx.doi.org/10.1016/j.immuni.2008.02.020
26. A.C.Campi-Azevedo, P.D.A.EstevamP de A, J.G.Coelho-dos-Reis, V.Peruhype-Magalhães, G.Villela-Rezende, P.F.Quaresma, M.D.L.S.MaiaM de L S, R.H.G.Farias, L.A.B.Camacho, M.D.S.FreireM da S, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis 2014; 15:14-391
27. A.C.Shaw, D.R.Goldstein, R.R.Montgomery. Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013; 13:875-87; PMID:24157572; http://dx.doi.org/10.1038/nri3547
28. V.Peruhype-Magalhães, O.A.Martins-Filho, A.Prata, L.D.A.SilvaL de A, A.Rabello, A.Teixeira-Carvalho, R.M.Figueiredo, S.F.Guimarães-Carvalho, T.C.Ferrari, J.Van Weyenbergh, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 2006; 146: 124-32; PMID:16968407; http://dx.doi.org/10.1111/j.1365-2249.2006.03171.x
29. M.L.Silva, M.A.Martins, L.R.Espírito-Santo, A.C.Campi-Azevedo, D.Silveira-Lemos, J.G.Ribeiro, A.Homma, E.G.Kroon, A.Teixeira-Carvalho, S.M.Elói-Santos, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 2011; 29:583-92; PMID:20732465; http://dx.doi.org/10.1016/j.vaccine.2010.08.046